Faculty

Celestia S. Higano, MD

Celestia S. Higano, MD FACP

Professor
Department of Medicine
Division of Oncology
Professor, Department of Urology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave W, MS: G4-830
Seattle, WA 98109-1023

Admin Contact

Jane Norris
206.288.1152
knorris@seattlecca.org
Fax: 206.288.2042

Specialty / Expertise

  • GU Oncology
  • Prostate Cancer

Research Interests

  • Palliative Care
  • Sexual Rehabilitation
  • Androgen deprivation therapy

Current Research Projects

A Phase I Open-Label Dose-Escalation Safety and Pharmacokinetic Study of MDV3100 in Patients with Castration-Resistant Prostate Cancer
Role: Site PI

A Randomized Phase 2 Study of Docetaxel/Prednisone with or without MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Castration-Resistant Prostate Cancer Preceded by a Phase 1 Dose-Escalation
Role: Site PI

A Randomized, Multicenter, Single Blind Study in Men with Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen
Role: Site PI

PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Nave Patients with Progressive Metastatic Prostate Cancer who have Failed Androgen Deprivation Therapy.
Role: Site PI

A Randomized Discontinuation Study of XL 184 Subjects with Advanced Solid Tumors
Role: Site PI

A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer
Role: International Co-PI

An Open-Label, Phase 1/2 Safety, Pharmacokinetic, and Proof-of-Concept Study of ARN-509 in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer
Role: Site PI

Enumeration of Circulating Tumour Cells in Patients Enrolled in Protocol OGX-011-11
Role: Site PI

A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer
Role: Site PI, Member Steering Committee

A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients with Metastatic Castration-Resistant Prostate Cancer.
Role: Site PI

A Phase I/IIa Study of Safety and Efficacy of Alpharadin with Docetaxel in Patients with Bone Metastases from Castration-Resistant Prostate Cancer
Role: Site PI, member phase 1 working group

Immune Monitoring Protocol in Men with Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Role: Site PI

STRIVE: A Mulitcenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Men with Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy
Role: Site PI

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
Role: Site PI

A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Ascending Doses of AZD8186 in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient Advanced Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186 within Prospectively-validated PTEN-deficient Tumors
Role: Site PI

Phase II Trial to Evaluate Benefit of Early Switch from First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Role: Site PI

A Multicenter Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Role: Site PI

Training

Dr. Higano received her MD from the University of Massachusetts. She completed an Internal Medicine Residency at the Mayo Graduate School of Medicine and a Hematology/Oncology Fellowship at the University of Washington.

Selected Publications

Higano CS. (Special Series: Adult Survivorship) Sexuality and intimacy following definitive treatment and subsequent androgen deprivation therapy for prostate cancer.  J Clin Oncol. 2012 Oct 20;30(30):3720-5.  Erratum in: J Clin Oncol. 2013 Feb 20;31(6):824.

Kantoff P, Higano CS.  Integration of immunotherapy into the management of advanced prostate cancer.  Urol Oncol. 2012 Sep;30(5 Suppl):S41-547.

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators.  Abiraterone in metastatic prostate cancer without prevous chemotherapy.  N Engl J Med. 2013 Jan 10;368(2):138-148.

Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B, Corey E, Nelson PS, Vessella RL, Morrissey C.  Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.  Prostate. 2013 Jun;73(9):932-940.

Menon MP, Higano CS.  Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer.  Curr Oncol Rep. 2013 Apr;15(2):69-75.

Miller K, Moul JW, Gleave M, Fizazi K, Nelson JB, Morris T, Nathan FE, McIntosh S, Pemberton K, Higano CS.  Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.  Prostate Cancer Prostatic Dis. 2013 Jun;16(2):187-192.

Akfirat C, Zhang X, Ventura A, Berel D, Colangelo ME, Miranti CK, Krajewska M, Reed JC, Higano CS, True LD, Vessella RL, Morrissey C, Knudsen BS.  Tumor Cell Survival Mechanisms in Lethal Metastatic Prostate Cancer Differ Between Bone and Soft Tissue Metastases.  J Pathol. 2013 Jul;230(3):291-297.

Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.  Ann Oncol. 2013 Jul;24(7):1813-1821.

Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Sundaram SK, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, and Thompson, IM Jr.  Intermittent versus Continuous Androgen Deprivation in Prostate Cancer.  N Engl J Med 2013; 368:1314-1325.

Fizazi K, Higano C, Nelson J, Gleave M, Miller K, Morris T, Nathan F, McIntosh S, Pemberton K, Moul J.  Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer.  J Clin Oncol. 2013 May 10;31(14):1740-1747.

Higano CS.  Potential use of custirsen to treat prostate cancer.  Onco Targets Ther. 2013 Jun 25;6:785-797.

Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr.  Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.  Lancet Oncol. 2013 Aug;14(9):893-900.

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.  Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment.  Eur Urol. 2013 Aug 11. doi:pii: S0302-2838(13)00829-4. 10.1016/j.eururo.2013.08.008. [Epub ahead of print].

Cherrier MM, Anderson K, David D, Higano CS, Gray H, Church A, Willis SL.  A Randomized Trial of Cognitive Rehabilitation in Cancer Survivors.  Life Sciences 93 (2013) 617–622.

Liu G, Lu S, Wang X, Page ST, Plymate SR, Higano CS, Greenberg NM, Sun S, Li Z, Wu JD.  Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.  J Clin Invest. 2013 Oct 1;123(10):4410-4422.

Higano, CS.  Urological Cancer: Alpha-emitting radium-223: additional choices, more unknowns.  Nat Rev Clin Oncol. 2013 Nov;10(11):612-613. doi: 10.1038/nrclinonc.2013.168. Epub 2013 Sep 10.

Qu X, Randhawa G, Friedman C, Kurland B, Glaskova L, Coleman I, Mostaghel E, Higano C, Porter C, Vessella R, Nelson P.  A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.  PLoS One. 2013 Sep 30;8(9):e74671. doi: 10.1371/journal.pone.0074671.

Mulders PFA, Molina A, Marberger M, Saad F, Higano CS, Chi KN, Kheoh T, Haqq CM, Fizazi K.  Efficacy and Safety of Abiraterone Acetate in Elderly (≥75 Yr) Patient Subgroup with Metastatic Castration-resistant Prostate Cancer Post-Docetaxel-Based Chemotherapy.  Eur Urol. 2013 Sep 20. doi:pii: S0302-2838(13)00992-5. 10.1016/j.eururo.2013. 09.005.  [Epub ahead of print]

Quinn DI, Shore N, Beer T, Higano CS, Vaishampayan U, Lin D.  Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.  Expert Rev Anticancer Ther. 2013 Jan;14(1):51-61.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M.  Prostate Cancer, version 1.2014.  J Natl Compr Canc Netw. 2013 Dec 1; 11(12):1471-1479.

Last updated: February 2014

Top